Educational Seminar "KazSMO Educational Intensive"

Opening Ceremony

Welcome addresses by the Organizing Committee and representatives of the Kazakhstan School of Medical Oncologists and the Kazakh Institute of Oncology and Radiology; official opening of KazSMO: OncoCourse 2026.

Opening Remarks

Woo Jin Hyung, MD, Professor

Yonsei University College of Medicine

Surgical Management of Gastric Cancer

Current approaches in gastric surgery, minimally invasive and laparoscopic techniques, and the role of surgery within multidisciplinary treatment.

10:00–10:10 · Q&A

Sinan Karaaslan, MD

Anadolu Medical Center

Systemic Therapy for Gastric Cancer

Perioperative and palliative chemotherapy, HER2- and Claudin18.2-targeted therapy, and immunotherapy approaches in gastric cancer.

10:35–10:45 · Q&A

Daniele Regge, MD, Professor

Istituto Nazionale Oncologico Candiolo

Screening for lung cancer: where we stand and where are we going?

Current approaches to lung cancer screening and early detection, including low-dose CT, followed by principles of clinical staging using modern imaging and invasive mediastinal staging techniques, with emphasis on their role in treatment decision-making.

11:40–11:50 · Q&A

Hasan Fevzi Batirel, MD, PhD

Memorial Goztepe Hospital

Changing Trends in the Treatment of Locally Advanced Non-Small Cell Lung Cancer

Patient selection and the optimal indications for surgery in locally advanced non-small cell lung cancer in the era of neoadjuvant chemoimmunotherapy.

12:20–12:30 · Q&A

Banu Atalar, MD

Radiation Therapy for Lung Cancer

Modern radiotherapy technologies (SBRT, IMRT), and the role of radiotherapy in localized and metastatic disease.

13:10–13:25 · Q&A

Javier Garde, MD

Valencian Institute of Oncology

Systemic Therapy for Driver Mutation-Negative Lung Cancer

Current chemotherapy regimens and immunotherapy approaches for driver mutation-negative NSCLC, combination strategies, and personalized treatment selection.

15:15–15:30 · Q&A

Systemic Therapy: Treatment of Driver Mutation-Positive Lung Cancer

Targeted therapy approaches for driver mutation-positive NSCLC, sequencing of targeted agents, and management of resistance.

16:15–16:30 · Q&A

Q&A and Closing of the Day's Session

Opening Remarks

Masahiro Nakashima, MD, PhD, Professor

Atomic Bomb Disease Institute; Nagasaki University

Thyroid Cancer Pathology: From Morphology to Molecular Diagnosis

09:50–10:00 · Q&A

Hirokazu Kurohama, MD, PhD, Assistant Professor

Atomic Bomb Disease Institute; Nagasaki University

Pathology of Lung Cancer: From Histological Diagnosis to Biomarker Testing

10:45–10:55 · Q&A

Opening Remarks

Mikael Hartman, MD, Associate Professor

NUS Yong Loo Lin School of Medicine; NUS Saw Swee Hock School of Public Health; Breast and Trauma Surgery, Department of Surgery, National University Hospital

Next generation Breast Cancer Screening

Global and regional epidemiology of breast cancer, disease burden, screening programs, stage distribution, mortality trends, disparities in outcomes, and future priorities in breast cancer control.

12:05–12:20 · Q&A

Ashutosh Mishra, MD, FACS, FSSO, Fellow-ESSO, Fellow UICC; MS, FAIS, FMAS, FIAGES, FARIS; MBA, Associate Professor

Dr. BRA-IRCH & National Cancer Institute (NCI); All India Institute of Medical Sciences (AIIMS)

Surgical Management of Breast Cancer

Breast-conserving surgery, oncoplastic techniques, sentinel lymph node biopsy, axillary de-escalation, management after neoadjuvant therapy, and current surgical guidelines.

13:00–13:10 · Q&A

Nazgul Omarbayeva, MD

Kazakh Institute of Oncology and Radiology

Treatment Decision According to Molecular Features

Molecular profiling in breast cancer, clinically relevant biomarkers, genomic assays, and integration of molecular features into personalized treatment selection and clinical decision-making.

13:30–13:40 · Q&A

Thomas Mulliez, MD, Professor

AZ Delta; Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel

Radiation Therapy for Breast Cancer

Modern radiotherapy techniques, hypofractionation, partial breast irradiation, regional nodal irradiation, post-mastectomy radiotherapy, and individualized treatment planning.

15:15–15:30 · Q&A

Samuel Ow, MD, M.Med, MPH, Associate Professor

National University of Singapore; National University Cancer Institute

Systemic Therapy for Early Breast Cancer

Contemporary neoadjuvant and adjuvant treatment strategies for HR-positive, HER2-positive, and triple-negative breast cancer, including immunotherapy, PARP inhibitors, CDK4/6 inhibitors, antibody-drug conjugates, and treatment individualization according to international guidelines.

16:15–16:30 · Q&A

Kaldygul Smagulova, Candidate of Medical Sciences (PhD), Associate Professor

Kazakh Institute of Oncology and Radiology

Systemic Therapy: Advanced Breast Cancer

Current treatment sequencing for HR-positive, HER2-positive, HER2-low and triple-negative metastatic breast cancer, targeted therapies, antibody-drug conjugates, management of resistance, and future treatment strategies

Q&A and Closing of the Day's Session

Ramil Abdrakhmanov, MD, PhD, Associate Professor

Kazakh Institute of Oncology and Radiology

Bispecific Antibodies in EGFR-Mutant NSCLC: Shifting the Therapeutic Paradigm

Supported by Johnson & Johnson

Aliya Turesheva, MD, PhD

Almaty Oncology Center

Beyond TKI Monotherapy: Redefining First-Line Treatment in EGFR-Mutant NSCLC

Supported by Johnson & Johnson

Rabiga Kadyrbayeva, MD, PhD (C)

Kazakh Institute of Oncology and Radiology

Perioperative Immunotherapy in Resectable NSCLC: From Patient Selection to Treatment Strategy - A Case-Based Approach

Supported by KFK

Kaldygul Smagulova, Candidate of Medical Sciences (PhD), Associate Professor

Kazakh Institute of Oncology and Radiology

Modern Standards and Debatable Issues in Immunotherapy for Lung Cancer

Supported by Roche

Valeriy Makarov, MD, PhD

National Research Oncology Center, Astana

Rebiopsy in NSCLC: From Molecular Need to Surgical Decision-Making

Supported by AstraZeneca

Rabiga Kadyrbayeva, MD, PhD (C)

Kazakh Institute of Oncology and Radiology

ALK-Positive NSCLC: Addressing Diagnostic Heterogeneity and the Evolving Role of Targeted Therapy in Adjuvant and Metastatic Settings

Supported by Roche

Assel Issimbayeva, MD

Multidisciplinary Medical Center, Astana

Immune-Related Adverse Events in Lung Cancer: Recognition, Management, and Rechallenge

Supported by KFK

Lorenza Landi, MD

IRCCS Regina Elena National Cancer Institute, Rome

TBC

Supported by Pfizer

Satellite Symposium: High-protein nutrition. How to improve patient's outcome and save hospital budget

Supported by Nutricia

Kaldygul Smagulova, Candidate of Medical Sciences (PhD), Associate Professor

Kazakh Institute of Oncology and Radiology

TBC

Supported by AstraZeneca

TBC

Speaker: TBC. Supported by Novartis

Gulzhanat Kaidarova

Kazakhstan

Abemaciclib in Combination with Endocrine Therapy: The Next Steps in the Treatment of High-Risk Early Breast Cancer

Supported by Swixx BioPharma

Optimizing Chemotherapy Delivery in the Day Hospital Setting: Safety, Efficiency, and Patient Convenience

Speaker: TBC. Supported by Medac

TBC

Speaker: TBC. Supported by Rogers Pharma

TBC

Speaker: TBC. Supported by Rogers Pharma